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Systemic anticancer chemotherapy is immunosuppressive and mostly induces nonimmunogenic 
tumor cell death. Here, we show that even in the absence of any adjuvant, tumor cells dying 
in response to anthracyclins can elicit an effective antitumor immune response that 
suppresses the growth of inoculated tumors or leads to the regression of established 
neoplasia. Although both antracyclins and mitomycin C induced apoptosis with caspase 
activation, only anthracyclin-induced immunogenic cell death was immunogenic. Caspase 
inhibition by Z-VAD-fmk or transfection with the baculovirus inhibitor p35 did not inhibit 
doxorubicin (DX)-induced cell death, yet suppressed the immunogenicity of dying tumor 
cells in several rodent models of neoplasia. Depletion of dendritic cells (DCs) or CD8
 
  
 
T cells 
abolished the immune response against DX-treated apoptotic tumor cells in vivo. Caspase 
inhibition suppressed the capacity of DX-killed cells to be phagocytosed by DCs, yet had no 
effect on their capacity to elicit DC maturation. Freshly excised tumors became immunogenic 
upon DX treatment in vitro, and intratumoral inoculation of DX could trigger the regression 
of established tumors in immunocompetent mice. These results delineate a procedure for the 
generation of cancer vaccines and the stimulation of anti-neoplastic immune responses in vivo.
 
The complete and permanent success of non-
surgical cancer therapy relies on the targeting
of all tumor cells, including cancer stem cells,
or theoretically on the direct removal of a frac-
tion of the tumor accompanied by a “bystander
effect” in which the immune system recognizes,
attacks, and eradicates the remaining tumor cells,
including cancer stem cells. Unfortunately,
however, most widely used cytotoxic antican-
cer agents exert immunosuppressive side effects.
Even worse, the preponderant type of cell
death induced by chemotherapy is apoptosis,
and apoptosis is frequently but not unani-
mously viewed as immunologically silent
(leading to ignorance by the immune system)
or even as tolerogenic (actively down-regulating
the specific antitumor immune response; refer-
ences 1 and 2). Thus, even after an initial ther-
apeutic success, patients typically fail to mount
a clinically relevant antitumor immune response
and eventually succumb to tumor cell variants
that escape from chemotherapy.
Although apoptosis is itself nonuniform
with respect to the programmed signaling
events responsible for cell death (3, 4), it is
morphologically defined as a uniform type of
cell death accompanied by chromatin conden-
sation (pyknosis) and nuclear fragmentation
(karyorhexis) occurring within an intact plasma
membrane (5, 6). Therefore, it differs from
necrosis in which the plasma membrane is
destroyed early during the death process. In
biochemical terms, apoptosis is frequently ac-
companied by the activation of a specific subset
of cysteine kinases, the caspases (4). Because
apoptosis is a physiological process that attains
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several millions of cells per second in the human body, it is
inferred that this type of cell death occurs without emitting
“danger signals” that would elicit a productive immune re-
sponse (7). Apoptotic cells would hide away from immune
recognition because they would be rapidly recognized and
silently phagocytosed in an efficient manner. Thus, defects in
the recognition/phagocytosis of apoptotic cells breach auto-
tolerance and trigger autoimmune reactions (8–10). More-
over, apoptotic cells would mediate active immunosuppression
by inhibiting the production of immunostimulatory cytokines
(e.g., interleukin 1
 
 
 
 by macrophages and interleukin 12 by
DCs; references 11 and 12), by stimulating the production of
immunosuppressive factors (e.g., transforming growth factor;
reference 13), and/or by eliciting antigen-specific immune
tolerance (14–16). In apparent contrast with this notion,
however, DCs can capture apoptotic tumor cells in vitro and
cross-present antigen derived from internalized dying cells
on MHC class I molecules for recognition by CD8
 
 
 
 T cells
in vivo, thus eliciting a productive immune response (2, 17–
22), including in clinical trials (23). Systematic comparisons
of the immunogenicity of apoptotic versus necrotic tumor
cells have been inconclusive (24–27), however, suggesting
that the nature of tumor cells and/or that the death-inducing
stimulus would influence the experimental outcome (1).
Driven by these uncertainties and incognita, we decided
to explore the possibility of inducing immunogenic tumor
cell apoptosis by chemotherapy. Here, we show that anthra-
cyclins are capable of eliciting immunogenic cell death in
vitro, ex vivo, and in vivo. These data may have profound
implications for the design of chemotherapeutic regimens
with immunogenic properties.
 
RESULTS
A mouse model of vaccination with apoptotic cancer cells
 
The colon carcinoma CT26 line was killed by treatment
with doxorubicin (DX) or mitomycin C (MC) as deter-
mined by FACS analysis (Fig. 1 A), although the phenotypic
manifestations of cell death differed. Both DX and MC in-
duced caspase activation (Fig. 1 B) and chromatin conden-
sation (Fig. 1, C and D), but only MC led to terminal
desoxyribonucleotidyl transferase dUTP nick end labeling
(TUNEL)-detectable DNA fragmentation (Fig. 1 C). When
combined with DX, the broad spectrum caspase inhibitor
Z-VAD-fmk (DXZ) delayed cell death (Fig. 1 A), reduced
caspase activation (Fig. 1 B), and blunted chromatin conden-
sation (Fig. 1 D). However, DXZ-treated cells manifested a
strongly reduced clonogenic survival as compared with un-
treated controls, indicating that most of the cells underwent
delayed caspase-independent death in vitro (Fig. 1 E) in ac-
cord with previous reports that DX can kill cells in the pres-
ence of caspase inhibitors (28, 29). Moreover, as compared
with untreated controls, DX- and DXZ-treated cells gener-
ated tumors with a significant delay after inoculation into
athymic 
 
nu/nu
 
 mice (Fig. 2 A). No tumor growth was found
when DX-, DXZ-, or MC-treated cells were inoculated
into syngenic, immunocompetent BALB/c mice (Fig. 2 B).
To explore the putative immunogenicity of dead or dying
cells, BALB/c mice were inoculated into one flank with live
CT26 cells and, simultaneously, received an injection of
DX-, DXZ-, or MC-treated or necrotic (frozen-thawed
[F/T]) cells into the opposite flank. In this therapeutic regime,
only DX-treated, but not DXZ-, MC-, or F/T-treated, cells
reduced the frequency of tumors developing from live cells
by 
 
 
 
45% on day 30 and 
 
 
 
30% on day 120 (Fig. 2 C). This
degree of protection was obtained without the addition of
any adjuvant. It was also independent of the presence of xe-
nogenic antigens (FCS) in the culture media (not depicted).
Animals not developing tumors after challenge with DX-
treated CT26 cells (5 out of 15) were protected against a sec-
Figure 1. In vitro characterization of the different cell death 
modalities induced in CT26 cells. (A) FACS analysis of cells treated in 
vitro with the indicated agents as specified in Materials and methods. 
ZVAD, Z-VAD-fmk. Numbers indicate the percentage of cells (X   SD, 
n   5) in each quadrant. (B) Immunoblot analyses of cells treated as in A. 
Cellular extracts were subjected to the immunodetection of activated 
caspase 3 (Casp3a), HMGB-1, and HSP-70. (C) TUNEL staining (green) 
of cells counterstained with DAPI (blue). The percentage of TUNEL  cells 
(X   SEM, n   3) was determined. (D) Transmission electron microscopy. 
Representative microphotographs are shown. Apoptotic cells showing 
chromatin condensation are labeled with an “A.” (E) Cells treated with 
the indicated agents as in A were washed and plated to determine the 
frequency of surviving clones, defining the control value of untreated cells 
as 100%. Results are representative of three independent experiments. 
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ond inoculation of live CT 26 cells, but were not immune
against the unrelated murine mammary adenocarcinoma TS/A
(TSA) tumor (Fig. 2 D). Similarly, the isolated cases of an-
imals not developing tumors after challenge with DXZ- or
MC-treated CT26 cells (2 out of 28 and 1 out of 16, respec-
tively) failed to develop tumors after rechallenge with live
CT26 cells (not depicted), indicating that these treatments
(DXZ and MC) could confer long-term antitumor immu-
nity, albeit at a much lower level of efficacy as compared
with DX-treated tumor cells. Splenic T cells from animals
protected by inoculation of DX-treated cells could transfer
efficient antitumor immunity when injected into naive re-
cipients (Fig. 2 E). Of note, the efficacy of the tumor vacci-
nation could be improved to 80% by one prophylactic injec-
tion of DX-treated cells before challenge with live tumor
cells. Regardless of the immunization schedule, DX-treated
cells did confer a higher degree of protection than DXZ-,
MC-, or F/T-treated cells (Fig. 2 F). Moreover, DX-treated
cells tended to be more immunogenic than CT26 cells dying
after 
 
 
 
 irradiation in the experimental setting of prophylactic
inoculation of dead cells 1 wk before injection of live tumor
cells into the opposite flank (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20050915/DC1). Other
anthracyclins than DX, such as daunorubicin and idarubi-
cin, also induced immunogenic cell death (Fig. 2 G). Thus,
dying tumor cells can elicit an effective antitumor im-
mune response. We wondered whether the chemical nature
of anthracyclins could be sufficient to explain the immuno-
genicity of DX-treated cells. Thus, CT26 cells were killed
with MC and then treated with DX for 15 min in conditions
that lead to DX incorporation into the cells at a level similar
to that of cells killed by 24-h culture with DX (Fig. 3 A).
However, the delayed treatment with DX did not amelio-
rate the poor immunogenicity of tumor cells killed by expo-
Figure 2. Immunogenicity of the different cell death types. (A) Tumor 
evolution of DX- and DXZ-treated cells in nu/nu mice. Cells treated as in 
Fig. 1 were injected subcutaneously (3   106/mouse). (B) Tumor evolution 
of DX- and DXZ-treated cells in immunocompetent BALB/c. Note that MC- 
or F/T-treated mice also did not form tumors. (C) Immunogenic effect of 
DX-treated tumor cells. BALB/c mice were injected into one flank with live 
tumor cells and into the opposite flank with DX-, DXZ-, MC-, or F/T-treated 
cells, and the evolution of tumors was monitored. (D) Persistent, specific 
antitumor immunity elicited by DX-treated cells. Animals immunized with 
DX-treated CT26 cells that remain tumor-free after 120 d (see lower left 
panel in C) or age-matched control mice were challenged with CT126 cells 
or the unrelated TSA tumor cell line. (E) Adoptive transfer of antitumor 
immunity elicited by DX-treated cells. BALB/c mice were injected intrave-
nously with 107 splenocytes from naive control animals or animals immu-
nized with DX-treated CT26 cells that remain tumor-free (as in B and D) 
followed by subcutaneous injection of 5   105 tumor cells. (F) Effect of 
the timing of antitumor vaccination. CT26 cells treated as in Fig. 1 were 
injected at the same time as live tumor cells (simultaneous injection as 
in C) or were injected once 1 wk before challenge with live tumor cells 
(prophylactic immunization; n   15 per group). (G) Replacement of DX by 
other anthracyclins. Animals were injected with CT26 cells treated with 
daunorubicin (DA) or idarubicin (ID), instead of DX, or PBS only (CO), and 
the growth of live CT26 cells simultaneously injected into the opposite 
flank was monitored as in C. All figures represent three to six independent 
experiments. *, P   0.05 versus control (CO). Note that growth curves of 
tumors are only shown to the level at which ethical guidelines oblige to 
kill the animals.
Figure 3. Contribution of DX to the immunogenic nature of apop-
totic tumor cells. (A) DX incorporation into CT26 cells. Tumor cells were 
treated in the absence or presence of DX for 24 h as in Fig. 1, and the 
incorporation of DX into cells was measured by assessing the DX-specific 
red fluorescence in the FACS (left). Alternatively, CT26 cells were killed by 
prolonged culture in MC (as in Fig. 1) followed by the optional addition of 
DX during the last 15 min of culture, washing, and determination of the 
DX incorporation (right). (B) Immunogenic effect of DX in vivo. Cells treated 
as in A (DX, MC, or MC plus DX) were injected subcutaneously in a prophy-
lactic setting (as in Fig. 2 F) 1 wk before challenge with life CT26 cells in 
the opposite flank followed by monitoring of tumor growth. 
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sure to MC, as compared with cells killed with DX (Fig. 3
B). Thus, it is the mode of cell killing rather than the pres-
ence of DX itself that explains the immunogenicity of DX-
treated tumor cells.
 
Immunogenicity of caspase-dependent, DX-induced 
cell death
 
As shown above, DX induced immunogenic tumor cell
death. However, concomitant treatment with the broad-
spectrum caspase inhibitor Z-VAD-fmk (DXZ) abolished
the immunogenic potential of the treatment with DX (Fig.
2, C and F). Similar inhibitory effects were obtained when
Z-VAD-fmk was replaced by a chemically related caspase
inhibitor with a narrow spectrum of action, such as Z-DEVD-
fmk (specific for caspase 3), whereas Z-VQID-CHO or
Z-VDVAD-CHO, which are specific for caspases 6 and 2,
respectively (not depicted), have no such effects. Z-VAD-
fmk did not ameliorate the clonogenic survival of DX-
treated CT26 cells (Fig. 1 E), nor did it reduce the incorpo-
ration of DX, which emits a red fluorescence, into the cell
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20050915/DC1). To confirm that caspases rather than
other proteases inhibited by Z-VAD-fmk (30) mark the dif-
ference between highly immunogenic (DX) and less immu-
nogenic (DXZ) death, we stably transfected CT26 cells with
the baculovirus caspase inhibitor p35, a protein that confers
highly specific, irreversible caspase inhibition in vitro and in
transgenic models (31, 32). Similarly to Z-VAD-fmk, p35
delayed DX-induced cell death (Fig. 4 A), yet did not re-
store the in vitro clonogenicity of DX-treated cells (Fig. 4
B). p35-expressing tumor cells failed to form tumors when
treated in vitro with DX and inoculated into immunocom-
petent mice. However, as opposed to vector-only trans-
fected DX-treated controls, p35-transfected DX-treated
CT26 cells failed to elicit an antitumor immune response
(Fig. 4, C and D). Animals protected against CT26 wild-
Figure 4. Inhibition of immunogenicity by the caspase inhibitor 
p35. (A) FACS analysis of CT26 cells transfected with vector only (Neo) or 
p35 cultured alone or in the presence of DX as in Fig. 1 A. Numbers indi-
cate the percentage of cells (X   SD, n   5) in each quadrant. (B) Clono-
genic survival of Neo or p35-transfected cells left untreated (100% values) 
or treated with DX. (C and D) Evolution of CT26 tumors in animals injected 
simultaneously with Neo-transfected, DX-treated, or p35-transfected 
DX-treated cells into the opposite flank. Note that only Neo-expressing 
DX-treated cells confer tumor immunity (P   0.01).
Figure 5. Effect of dying tumor cells on DCs. (A and B) In vitro 
phagocytosis of the DX-, DXZ-, or MC-treated cells (stained with CMTMR) 
by spleen DCs from Flt3L-injected mice. Representative FACS diagrams are 
depicted in A, and confocal images of dying tumor cells (red) phagocy-
tosed by purified DC subsets (green) are shown in B. (C) DC maturation of 
splenic DCs induced by LPS (positive control) and dying or dead CT26 cells. 
Percentage values in A and C are means of three independent determina-
tions   SD. (D) Failure of Z-VAD-fmk to inhibit the phagocytosis of DX-
treated CT26 cells by DCs. DCs generated as in D were incubated for 90 
min with a twofold excess of DX-treated CT26 cells in the presence of 
the indicated concentrations of Z-VAD-fmk, and the percentage of DCs 
containing dying or dead CT26 cells was determined as in A. (E) Failure 
of DX to activate DCs. Bone marrow–derived DCs were activated with LPS 
as a positive control or with the indicated concentration of DX, and the 
frequency of apoptotic cells (annexin V ) and CD86  cells was determined 
by immunofluorescence and cytofluorometric analysis. Percentage values 
in A and C–E are means of three independent determinations   SD. 
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type tumors also failed to develop tumors after inoculation of
live p35-expressing CT26 cells, indicating that p35 did not
interfere with the effector arm of the immune system (not
depicted). Thus, two different protocols of caspase inhibition
(pharmacological in the case of Z-VAD-fmk and genetic and
cell-autonomous in the case of p35) had similar effects on
the immunogenicity of DX-treated tumor cells.
 
Critical role of DCs in the immune response elicited by dying 
tumor cells
 
In an attempt to understand why DX-induced cell death
is immunogenic, we challenged DCs with dead or dying
cells and measured their response. DX-treated CT26 cells
were phagocytosed by all CD11c
 
 
 
/IA
 
d
 
 
 
 DC subpopulations
(CD11b
 
 
 
 B220
 
 
 
 DCs in Fig. 5 A and CD8
 
 
 
 
 
 DCs not
depicted) present in the spleen, whereas nonimmunogenic
(live, DXZ, MC, or F/T) CT26 cells were neglected by
DCs (Fig. 5, A and B). In contrast, several categories of dy-
ing (DX, DXZ, and F/T but not MC) tumor cells possessed
the capacity of inducing DC maturation, as indicated by in-
creased expression of the costimulatory molecules CD80 and
CD86 as well as induction of MHC class II (Fig. 5 C). Solu-
ble DX itself did not activate CD86 (Fig. 5 C) or CD80 (not
depicted) expression in bone marrow–derived DCs when
used at concentrations that cause apoptosis of a fraction of
DCs (Fig. 5 D). Moreover, Z-VAD-fmk did not inhibit the
DC-mediated phagocytosis of DX-treated CT26 cells (Fig. 5
E). Thus, the differential effect of MC-, DX-, and DXZ-
treated cells on DCs cannot be due to the carryover of solu-
ble DX or Z-VAD-fmk. DX-treated, but not DXZ-treated,
CT26 cells elicited a cytotoxic T cell response after in vivo
inoculation (Fig. 6 A). An intact cellular immune system was
required for the DX-elicited immunogenic effect because
athymic 
 
nu/nu
 
 mice failed to mount a productive antitumor
immune response when challenged with DX-treated CT26
cells (Fig. 6 B). Similarly, the selective depletion of CD8
 
 
 
cells, but not that of NK cells, by in vivo injection of specific
mAbs abolished the antitumor immune response stimulated
by DX-treated cells (Fig. 6 C). Thus, NK cells are dispens-
able for the antitumor immune response elicited by DX-
treated cells, whereas CD8
 
 
 
 cells are required for this re-
sponse. Additional data indicating the importance of CTLs
were obtained in other tumor-relevant models. Injection of
OVA-transfected B16F10 melanoma cells elicited the local
recruitment of OVA-specific CD8
 
 
 
 T cells, which recog-
nize the K
 
b
 
/SIINFEKL tetramer, into (as well as the produc-
tion of IFN-
 
 
 
 by cells from) the draining lymph node of
syngenic C57BL/6 mice, provided that the injected cells
were pretreated with DX (Fig. 7, A–C). However, this re-
sponse was blunted when the inoculum had been treated
with DXZ or MC, or when the DX-treated cells were ren-
dered necrotic by freeze-thawing (Fig. 7, A–C). To de-
termine the impact of CD11c
 
 
 
 DCs on the immune re-
sponse in vivo, diphteria toxin was injected into transgenic
C57BL/6 mice expressing the diphteria toxin receptor spe-
cifically in DCs (under the control of the CD11c promoter;
reference 33). Vehicle-injected control animals recruited
CD8
 
 
 
 T cells with a TCR specific for the OVA-derived
K
 
b
 
/SIINFEKL epitope into the draining lymph node, but
DC-depleted animals failed to do so in response to injection
of apoptotic OVA-transfected B16F10 cells (Fig. 7 D).
These data confirm that DX-treated cells are particularly ef-
fective in stimulating a cytotoxic immune response and that
this response is mediated by DCs.
 
DX-elicited apoptosis is immunogenic in several tumor models
 
One single subcutaneous injection of DX-treated CT26 cells
conferred a strong protection against the development of pul-
monary metastases induced by simultaneous intravenous injec-
tion of tumor cells (Fig. 8 A). In this system, MC-treated and
F/T cells were inefficient. Freeze-thawing of DX-treated
CT26 cells (DX F/T) annihilated their immunogenic effect,
and coincubation with Z-VAD-fmk led to a partial reduction
of the DX effect (Fig. 8 A). The anti-metastatic effect was
complete when DX-treated CT26 cells were injected twice
before intravenous challenge with untreated CT26 cells (Fig. 8
B). In a further round of experiments, we determined whether
the observed tumor vaccination effects were a general phe-
nomenon. When replacing CT26 cells with B16F10 cells, we
Figure 6. Characterization of the immune effectors induced by 
dying tumor cells. (A) CTL response of DX- and DXZ-treated cells in 
immunized mice. Splenic T cells from animals vaccinated with PBS only 
(CO), DX-treated CT26 cells, or DXZ-treated CT26 cells were tested for their 
capacity to lyse syngenic cells pulsed with the immunodominant H2Ld-
restricted CT26-derived peptide SPSYVYHQF. Representative CTL responses 
from individual mice are shown on the left, and mean values are shown on 
the right. R and NR refer to responders and nonresponders, respectively. 
*, P   0.01 versus control (CO). (B) Failure of nude mice to mount an 
immune response against DX-treated CT26 cells. Wild-type or nu/nu BALB/c 
mice were inoculated with DX-treated CT26 cells 1 wk before the injection 
of live CT26 cells into the opposite flank, and tumor-free survival was 
monitored. (C) Requirement of CD8  but not NK cells for the antitumor 
immune response. Wild-type BALB/c mice received intraperitoneal injections 
of depleting antibodies specific for CD8 or for the NK marker asialo-GM1
3–4 d before challenge with dying (DX-treated) and live (untreated) CT26 
cells into opposite flanks at 1 wk of interval. 
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found that this melanoma cell line was immunogenic if DX
treated and injected into C57BL/6 mice (not depicted).
B16F10A2/gp100 melanoma cells present peptides from the
human gp100 tumor antigen in the context of HLA class I A2
(34). Again, in vitro treatment with DX followed by subcuta-
neous injection of the cells was able to induce a significant pro-
tection against later challenge with live B16F10A2/gp100
tumor cells in “humanized” mice expressing an HLA.A2 trans-
gene (Fig. 8 C; references 34 and 35). As a side observation,
such humanized mice were largely deficient for NKT cells
(NK1.1
 
 
 
 TCR
 
 
 
/
 
 
 
 
 
 CD4
 
 
 
; Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20050915/DC1), sug-
gesting that NKT cells are not required for the antitumor im-
mune response elicited by DX-treated tumor cells. Thus, DX-
treated dying tumor cells turned out to be immunogenic on a
human MHC background. Furthermore, inbred BDIX rats in-
oculated with the syngenic PROb colon carcinoma (36) could
be protected by injection of DX-treated tumor cells, and this
effect was again suppressed by simultaneous pretreatment of
the tumor cells with DX and Z-VAD-fmk (Fig. 8 D). In con-
clusion, this protocol of cancer immunization is applicable to a
series of distinct tumors, species, and MHC backgrounds.
 
Ex vivo and in vivo induction of immunogenic apoptosis
 
We investigated whether it would be required to immunize
animals with dying cells cultured as an established cell line or
whether it would be feasible to take advantage of resected
tumors (as this would be the case in human cancer patients).
CT26 tumors were generated in BALB/c mice and then sur-
gically removed and enzymatically dissociated optionally af-
ter a step of cryostorage in DMSO-containing medium,
treated with DX in vitro, and used as antitumor vaccine
(Fig. 9 A). This ex vivo removal/in vitro treatment elicited
an efficient antitumor immune response if DX was added
during the in vitro incubation, although cryostored cells
were less efficient than freshly recovered tumor cells. The
omission of DX curtailed the efficacy of the vaccine (Fig. 9
A). As an alternative to this ex vivo/in vitro protocol of vac-
cine generation, we injected DX into palpable (
 
 
 
125 mm
 
3
 
)
subcutaneous CT26 tumors established in BALB/c mice.
Using this protocol of intratumoral as opposed to intrave-
nous (not depicted) chemotherapy, we achieved stable dis-
ease or complete tumor regression in 16 out of 40 (40%) of
the animals (Fig. 9 B). We have no explanation why some
animals showed no therapeutic effect, others demonstrated a
Figure 7. Contribution of specific CTLs and DCs to the immune 
response against DX-treated tumor cells. (A) Percentages of CD8  lymph 
node cells expressing TCR that interact with the OVA-derived peptide SIINFEKL 
presented by H-2Kb 5 d after challenge with either peptide plus adjuvant 
(P A) or with DX, DX F/T (cells treated with DX and then F/T), DXZ-, MC-, 
and F/T-treated B16-OVA cells (three experiments). (B) Absolute number of 
specific CD8  cells per lymph node determined as in A. Values are X   SD 
(n   3). (C) IFN-  production as measured after in vitro culture with 
SIINFEKL in the same experiment. Control values are  50 pg/ml. (D) Effect 
of the depletion of DCs on the accumulation of specific T cells. Transgenic 
mice specifically expressing the diphteria toxin (DT) receptor in DCs were 
pretreated with PBS alone or a dose of diphteria toxin that depletes DCs. 
The mice were then challenged with DX-treated B16-OVA cells into the 
food pad. Draining lymph nodes were recovered 48 h later and stained for 
simultaneous detection of CD8 and OVA peptide–specific T cell receptors. 
Representative FACS pictograms are shown and values are X   SD (n   3).
Figure 8. Antitumor vaccination with DX-treated melanoma or 
colon carcinoma cells in distinct rodent models. (A) Percentage of 
metastasis-free mice observed after intravenous injection of live CT26 
cells into animals injected simultaneously with vehicle only (CO) or dying 
tumor cells generated as in Fig. 1. Untreated controls developed 46   22 
metastases (X   SD, n   46). (B) Effect of two immunizations with DX-
treated CT26 cells 14 and 7 d before intravenous injection of live CT26 
cells. Data in A and B have been pooled from three independent experi-
ments. *, P   0.001 versus control (CO). (C) DX-treated B16A2 cells were 
injected twice into mice transgenic for HLA.A2 1 and 2 wk before challenge 
with live B16A2 cells into the opposite flank. *, P   0.05 versus control 
(CO). (D) The protocol of simultaneous subcutaneous injection of dying 
(DX- or DXZ-treated) tumor cells was applied to BDIX rats challenged with 
PROb cells. *, P   0.001 versus control (CO). This experiment has been 
repeated three times, yielding similar results.JEM VOL. 202, December 19, 2005 1697
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delay in tumor growth, and yet others were completely
cured. One possible explanation for this heterogeneity is a
variation in the local infiltration of the tumor that escapes
macroscopic inspection. When DX was injected in combi-
nation with Z-VAD-fmk or when DX was replaced by MC,
we only observed a delay in tumor growth with no stable
disease or tumor regression (n   15; Fig. 9 B). Rechallenge
of animals that manifested a complete therapeutic response
with DX-treated CT26 cells failed to produce tumors (Fig. 9
C), indicating that this therapeutic regimen had induced a
persistent antitumor immunity. Importantly, DX injection
into tumors failed to yield a therapeutic response (beyond a
delay in tumor growth by several days) in nu/nu mice (Fig. 9
D), indicating that the immune system participated in the
beneficial effects of DX injection as observed in immuno-
competent mice (Fig. 9 B). When we investigated the effect
of intratumoral DX injection into tumors of BDIX rats car-
rying PROb cancers, we found again that the therapeutic ef-
fect of DX injection was only observed in immunocompe-
tent rats (not in athymic animals) and that its effect was
abolished by coinjection of Z-VAD-fmk (Fig. 9 E). Local
injection of MC caused a similar delay in PROb tumor
growth in immunocompetent and athymic rats (Fig. 9 E).
These findings corroborate the notion that DX causes im-
munogenic tumor cell death, whereas MC causes a nonim-
munogenic (or less immunogenic) type of cell death in vivo.
DISCUSSION
Apoptosis is often considered as an immunologically silent or
even tolerogenic death modality (8–16, 37). Challenging this
viewpoint, it has been shown that gemcitabine-induced ap-
optosis of hemagglutinin-expressing AB1 mesothelioma cells
can prime CD8 T cells in vivo, thus eliciting an effective an-
titumor immune response (38). Similarly, local   irradiation
of OVA-transfected B16F10 tumors can increase both the
generation of antitumor immune effector cells and their traf-
ficking to the tumor site (39). The present data suggest that
some but not all regimens of chemotherapy-induced apop-
tosis can elicit an effective antitumor immune response. Al-
though anthracyclins (and in particular DX, which we used
as a model agent) elicited immunogenic apoptosis in vitro
(Figs. 2–4 and 6–8), ex vivo (Fig. 9 A) and in vivo (Fig. 9,
B–E) MC (Figs. 2, 3, 5 C, 6 A, 7 A, 8 A, and 9 B) was rela-
tively inefficient in eliciting immunogenic cell death. The
incorporation of DX a posteriori into MC-killed cells could
not substitute for the DX treatment ab initio (Fig. 3), under-
scoring the contribution of the host cell (rather than the
chemical nature of anthracyclins) to the immunogenic phe-
notype. Preparations of DX- or MC-treated cells that con-
tained a similar percentage of dying cells (Fig. 1 A) were in-
jected, and the morphological aspect of cell death elicited by
DX and MC was similar (Fig. 1, C and D). Both were ac-
companied by caspase activation (Fig. 1 B) without any dif-
ference in the expression of some major endogenous adju-
vants, such as HSP70 and HMGB-1 (Fig. 1 B), and the only
difference resided in the degree of DNA fragmentation,
which was more advanced with MC (Fig. 1 C). Moreover,
DCs phagocytosed MC-treated cells less efficiently than
DX-treated cells (Fig. 5 A), thus underscoring a hitherto un-
Figure 9. Ex vivo and in vivo induction of immunogenic cell death. 
(A) Evolution of tumors in mice vaccinated with cells from freshly resected 
or cryopreserved CT26 tumors, which were left untreated (CO) or treated 
with DX. (B) Effect of intratumoral chemotherapy on the growth of CT26 
colon cancer cells inoculated into immunocompetent BALB/c mice. BALB/c 
mice previously inoculated with live CT26 cells received intratumoral 
injection (arrows) of DX, DXZ, or MC as soon as they were palpable  14 d 
after inoculation of tumor cells, and the tumor growth was monitored. 
Although some DX-treated animals showed a normal tumor growth (n   12) 
or a simple delay in tumor growth (n   12), other animals exhibited stable 
disease (n   7) or complete tumor regression (n   9). (C) Rechallenge of 
animals cured by intratumoral injection of DX (as in B) or age-matched 
control (CO) mice with live CT26 cells. Similar results were obtained in 
three independent experiments. (D) Failure of intratumoral DX injections 
to confer stable antitumor effects in nu/nu BALB/c mice carrying CT26 
tumors. The experiment was performed as in B except that the animals 
were immunodeficient. (E) Intratumoral injections in the PROb rat colon 
carcinoma model. Immunocompetent or nu/nu BDIX rats carrying PROb 
tumors received intratumoral injections of DX, DXZ, or MC, and tumor 
growth was monitored.ANTITUMOR VACCINATION | Casares et al. 1698
suspected heterogeneity in apoptotic cells with respect to
their uptake by DCs (40). Importantly, inhibition of caspase
activation by Z-VAD-fmk or transfected p35 greatly re-
duced the immunogenic potential of DX-treated cells, an ef-
fect that was observed in a variety of different tumor models
in vitro and in vivo (Figs. 2–9) and also affected DC-medi-
ated recognition and phagocytosis (Fig. 5 A). However,
caspase activation is not sufficient to elicit an immunogenic
cell death because MC-treated cells, which do exhibit
caspase activation (Fig. 1 B), are inefficient antitumor vac-
cines (Fig. 2). Thus, a specific combination of factors, caspase
activation, and a yet-to-be defined antigenic property of an-
thracyclin-treated cells have to cooperate to elicit an antitu-
mor immune response. Disruption of the membrane integ-
rity of DX-treated tumor cells by freeze-thawing is sufficient
to abolish their immunogenic property (Figs. 2 F, 7, A–C,
and 8 A), meaning that intact apoptotic cells or bodies are
required for optimal antigenicity. Induction of necrotic cell
death is usually achieved by several cycles (usually three or
more) of freeze-thawing, whereas we performed one single
freeze-thaw cycle, a procedure that avoids a gross liquefac-
tion of cellular structures. Thus, in contrast with other re-
ports (41, 42), freeze thawing as performed here did not re-
sult in the uptake of cells by DCs (Fig. 5 A) nor in
immunogenic cell death (Fig. 2 C). Regardless of these
mechanistic details, it appears that the particular protocol of
apoptosis induction determines the immunogenicity of cell
death. Apparently, two different subcategories of apoptosis
exist, one that is highly immunogenic and another that is
comparatively less immunogenic.
DX-treated dying tumor cells are efficiently phagocytosed
by myeloid and plasmacytoid DCs (Fig. 5, A and B) and are
highly efficient in eliciting antigen-specific CTLs (Figs. 6 A
and 7), which are required for the antitumor immune re-
sponse (Fig. 6, B and C). In contrast, NK cells (Fig. 6 C) and
NKT cells (Fig. S3) are not stringently required for mounting
an antitumor immune response, at least in this experimental
setting. Thus, in contrast to other experimental systems, such
as viral infection (43), NK cells are dispensable for the prim-
ing of DCs by DX-treated tumor cells. Of note, intratumoral
DX injection could elicit a chemotherapeutic response whose
positive outcome requires an intact cellular immune sys-
tem (Fig. 9, D and E). Again, these properties (phagocytosis
of DX-treated cells by DCs, induction of antigen-specific
CTLs, and elicitation of an immune response by intratumoral
injection of DX) were largely reduced by simultaneous treat-
ment with the caspase inhibitor Z-VAD-fmk, correlating
with a reduced immunogenicity. To our knowledge, this is
the first report indicating that caspase activation is broadly re-
quired for the elicitation of immunogenic tumor cell death.
Previous reports have described that caspase activation rather
reduces the immunogenic potential of tumor cells. Thus, a
PROb clone (REGb) that fails to activate caspases is much
more immunogenic than the parental PROb line (44). Simi-
larly, a PROb clone manipulated to stably express an anti-
sense cytochrome c cDNA undergoes atypical apoptosis with-
out caspase activation, yet has an increased immunogenic po-
tential (27). As another example, caspases have been docu-
mented to destroy immunodominant epitopes, thus blunting
the immune response against lymphoma cells (45). In NOD
mice, which are prone to develop autoimmune diabetes, sys-
temic caspase inhibition reduced the priming of T cells by  
cells undergoing spontaneous apoptosis (46) and, conversely,
local caspase inhibition abolished the tolerogenic effect of  
cell apoptosis induced by streptozotocin (37). The data pre-
sented here, which address the importance of caspase activa-
tion in a direct fashion, suggest that caspase activation amelio-
rates the antigenic properties of dying tumor cells. This points
to an interesting problem. The expression of caspase inhibi-
tors has negative prognostic value for some tumors (47–49).
It is possible that failure to activate caspases not only increases
the resistance of tumor cells to chemotherapeutic agents, in a
cell-autonomous fashion, but also reduces the probability of
immunogenic death, thus blunting the host’s antitumor de-
fense system.
It is important to underscore the fact that the immuno-
genic effects of anthracyclin-treated tumor cells were ob-
served in the absence of any adjuvant or costimulus. Hence,
coapplication of adjuvants might be expected to improve the
efficacy of the vaccination schedule. As a fascinating possibil-
ity, our data suggest a strategy of inducing immunogenic cell
death in established tumors either ex vivo or in vivo.
Whether such a simple strategy might be efficient in treating
patients has to be addressed in the future.
MATERIALS AND METHODS
Cell lines and cell death induction. CT26, PROb, B16F10, B16/
F10.9-OVA, and B16F10A2/gp100 (B16F10 transfected with gp100 and
HLA A2.1 and selected in 50  g/ml hygromicin and G418) cells were cul-
tured at 37 C under 5% CO2 in RPMI 1640 medium supplemented with
10% FCS, penicillin, streptomycin, 1 mM pyruvate, and 10 mM Hepes in
the presence of DX for 24 h (25  M for CT26, 30  M for PROb, and 2.5
 M for B16F10 and its derivatives), 5  M daunorubicin for 24 h (GE
Healthcare), 1  M idarubicin for 24 h (Aventis), 30  M MC for 48 h
(Sanofi-Synthelabo), and/or 100  M zVAD-fmk for 24 h (Bachem). Ne-
crosis was induced by one freeze-thaw cycle in liquid N2 and a 37 C water
bath. CT26 cells were stably transfected with vector only (Neo) or with a
pcDNA3.1 vector encoding p35 (31, 32). In one experiment, 100  M DX
was added for 15 min to cells cultured in MC for 2 d. The incorporation of
DX into washed (three times in PBS) cells was measured by assessing
the DX-specific red fluorescence in a FACSVantage (Becton Dickinson)
equipped with an argon laser.
Cell death assays. Cells were trypsinized and subjected to cytofluoromet-
ric analysis with a FACSVantage after staining with 2.5  M DAPI for 10
min (Invitrogen) for determination of cell viability, and annexin V was con-
jugated with fluorescein isothiocyanate (Bender Medsystems) for the assess-
ment of phosphatidylserine exposure (50, 51). TUNEL assays were per-
formed on cells (let to adhere for 1 h in PBS on polylysine-coated slides [O.
Kindler GmbH] and fixed with 4% paraformaldehyde for 30 min) using the
In situ Cell Death Detection Kit (Roche) and a fluorescence microscope
(IRE2; Leica) equipped with a camera (DC300F; Leica). For electron mi-
croscopy, cells (fixed for 1 h at 4 C in 2.5% glutaraldehyde in phosphate
buffer, pH 7.4, washed, and fixed again in 2% osmium tetroxide and thenJEM VOL. 202, December 19, 2005 1699
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embedded in Epon) and ultrathin sections (80 nm) were stained with uranyl
acetate and lead citrate and examined with an electron microscope (902;
Leo) at 80 kV.
Immunoblot analyses. Cells were washed with cold PBS at 4 C and
lysed in a buffer containing 50 mM Tris HCl, pH 6.8, 10% glycerol, and 2%
SDS. Primary antibodies detecting activated caspase 3 (dilution 1/1,000; Cell
Signaling Technology), HSP70 (dilution 1/1,000; Stratagene) or 2  g/ml
HMGB-1 (BD Biosciences) were revealed with the appropriate horseradish
peroxidase–labeled secondary antibody (Southern Biotechnology Associates,
Inc.) and detected by enhanced chemiluminescence (Pierce Chemical Co.).
Anti-actin or anti-GAPDH (Chemicon) was used to control equal loading.
Antitumor vaccination and assessment of tumor growth in vivo.
All animals were maintained in specific pathogen-free conditions, and all
experiments followed the Federation of European Laboratory Animal Sci-
ence Association guidelines. 3   106 treated CT26 cells were inoculated
subcutaneously in 200  l PBS into 6-wk-old female BALB/c mice (Charles
River Laboratories) into the lower flank, whereas 5   105 untreated control
cells were inoculated into the contralateral flank (52). PROb cells (3   106
treated cells and 106 control cells) were injected subcutaneously into the
lower flanks of syngeneic 2-mo-old BDIX rats (Charles River Laborato-
ries), and B16A2 and B16F10 (1.8   105 treated cells and 3   104 control
cells) were injected into 6-wk-old female HHD2 transgenic mice (bred in
the Institut Gustave Roussy [IGR] animal facility) and C57BL/6 mice
(Charles River Laboratories), respectively. For the tumorigenicity assay, 3  
106 treated or untreated CT26 cells were injected subcutaneously into
nu/nu mice (IGR animal facility). To assess the specificity of the immune
response against CT26, we injected either 5   105 or 5   106 of CT26 (for
the mice immunized in a standard protocol or vaccination protocol, respec-
tively) or 106 TSA cells. Tumors of the control side were evaluated weekly
using a caliper. Animals bearing tumors in excess of 20–25% of the body
mass were killed. In one series of experiments, splenocytes from naive or tu-
mor-protected BALB/c mice (i.e., mice that remain tumor-free for at least
60 d after subcutaneous challenge with apoptotic and live CT26 cells into
the right and left flanks, respectively) were injected intravenously (107 cells)
into 6-wk-old female BALB/c mice, which received 5   105 CT26 cells
subcutaneously 1 d later. Lung metastases were generated by injecting 105
CT26 cells into the tail vein simultaneously with a subcutaneous injection
of 3   106 treated cells. Mice were injected with Indian ink 20 d later,
killed, and lung metastases were counted with a loupe by three independent
investigators in a blind fashion. For vaccination with primary tumors, sub-
cutaneous tumors were dissected and dissociated with 1.6 mg/ml collage-
nase and 350 U/ml DNase for 20 min at 37 C, treated with 20  M DX for
24 h, and then injected subcutaneously with 3   106 cells. Alternatively, the
tumors were frozen (in FCS with 10% DMSO) as  1-mm3 cubes at  80 C
and dissociated and treated the same way after thawing. In a series of exper-
iments, BALB/c (wild-type or nu/nu) carrying palpable CT26 tumors or
rats (BDIX or nude) carrying PROb tumors (implanted 14 d before by in-
jection of 106 tumor cells) received a single intratumoral injection of MC
(100  l of a 3-mM solution), DX (20  l of a 10-mM solution), and/or
Z-VAD.fmk (10  l of a 100-mM solution). Depletion of CD8  or NK
cells was achieved by intraperitoneal injection of 250  g anti-CD8 mAb
(obtained from the rat anti–mouse hybridoma H35.17.2; American Type
Culture Collection) or anti-asialo GM1 mAb (Wako Bioproducts), respec-
tively, 4 d before challenge with dying (DX-treated) tumor cells and 3 d be-
fore injection of live tumor cells (inoculated 1 wk after that of the DX-
treated cells).
Assessment of specific T cell responses. The CTL response against the
immunodominant CT26-specific AH1 H2Ld-restricted peptide (SPSYVY-
HQF; Neosystem; reference 53) was determined. Splenocytes were isolated
from immunized mice 10 d after injection of apoptotic cells and restimu-
lated in vitro for 5 d with or without 5  g/ml AH1 in the presence of syn-
geneic irradiated naive spleen cells. The cytotoxic activity was determined
during a classic 5-h in vitro 51Cr-release assay using 51Cr-P815 tumor cells
loaded with 50  M AH1 peptide as target cells (52). The percentage of spe-
cific lysis was calculated as 100   (experimental release   spontaneous re-
lease)/(maximal release   spontaneous release). Maximum release was ob-
tained by adding 10% Triton X-405 to target cells, and spontaneous release
was determined by incubating target cells in medium alone. 5–6-wk-old fe-
male C57BL/6 mice (H-2b) were injected into both footpads with PBS and
50  g OVA peptide (H-2Kb-restricted, SIINFEKL, amino acids 257–264;
Eurogentec) mixed with incomplete Freund adjuvant (Sigma-Aldrich) or
106 B16/F10.9-OVA cells. Animals were killed 5 d after footpad immuni-
zation, and popliteal and inguinal lymph nodes were removed and pro-
cessed individually. A single cell suspension was obtained by homogenizing
and filtering the organ through a sterile cell strainer (70  m; Becton Dick-
inson). For FACS analysis, 2   106 cells were stained at room temperature
with a tetramer-OVA-PE (Beckman Coulter) and then stained with an
anti–CD3-FITC and an anti–CD8-APC mAb (Becton Dickinson). Cells
were analyzed using a FACSCalibur cytometer (Becton Dickinson) with
CELLQuest Pro software. Alternatively, 105 cells were cultured in complete
culture medium containing 2% of mouse serum in the presence or absence
of 40  g/ml SIINFEKL peptide. 3 d later, the supernatants were harvested
and IFN-  secretion was determined by ELISA (OptEIA ELISA Kit; BD
Biosciences). In one series of experiments, CD11c-GFP DT Kb mice (33)
were injected intraperitoneally with 100 ng diphteric toxin (or PBS as a ve-
hicle control) 48 h before the injection of DX-treated B16/F10.9-OVA
cells into the food pad.
Priming and isolation of DCs. Mice were injected intraperitoneally
daily with 10  g of Flt3L (Immunex) for 10 consecutive days. Splenic cells
were coincubated with 1  M CytoTracker Red– (CMTMR; Invitrogen)
prestained apoptotic or necrotic CT26 cells at a ratio of 1:1 or 5:1 for 2 h
for the phagocytosis experiments or 24 h for maturation experiments.
Cells were then analyzed by FACS with FITC-conjugated antibodies
(Becton Dickinson) specific for B220, CD11b, CD8 , MHC class II,
CD40, CD80, or CD86 molecules, as well as an APC-conjugated anti-
CD11c antibody. Alternatively, CD11c  splenocytes were purified using
immunomagnetic beads (Miltenyi Biotec) coincubated for 2 h with the
CMTMR-labeled CT26 cells at a ratio of 1:1. The cells were then stained
with B220, CD11b, and CD8  (BD Biosciences), as well as a goat anti–
mouse antibody conjugated with Alexa Fluor 488 (Invitrogen). Confocal
microscopy was performed with a microscope (LSM 510; Carl Zeiss Mi-
croImaging, Inc.) equipped with a 63X objective. For the generation of
bone marrow–derived DCs, bone marrow cells were flushed from the tib-
ias and femurs of C57BL/6 mice with RPMI 1640 medium supplemented
with 10% heat-inactivated FBS (Invitrogen), 2 mM L-glutamine, 50  M
2-ME (Sigma-Aldrich), 10 mM Hepes buffer, pH 7.4 (Invitrogen), and
50  g/ml penicillin/streptomycin (Invitrogen). After one centrifugation,
bone marrow cells were resuspended in Tris-ammonium chloride for 2
min to lyse red blood cells. After one more centrifugation, bone marrow
cells were cultured for 8 d at 106 cells/ml in culture medium supple-
mented with 100 ng/ml recombinant mouse FLT3 liter (R&D Systems) in
six-well plates (Costar Corning).
Statistical analyses. Data are presented as arithmetic means   SD or per-
centages. All statistical analyses were performed using JMP software (SAS
Institute Inc.). The Student’s t test was used to compare continuous vari-
ables (comparison of tumor growth), the Chi square test was used for non-
parametrical variables (comparison of animal cohorts), and log-rank tests
were used for Kaplan Meier curves. For all tests, the statistical significance
level was set at 0.05.
Online supplemental material. Fig. S1 shows the immunogenicity of
 -irradiated apoptotic CT26 cells in vivo.  Mice were immunized by a pro-
phylactic injection of  -irradiated CT26 cells before challenge with live tu-ANTITUMOR VACCINATION | Casares et al. 1700
mor cells.  Fig. S2 is a cytofluorometric analysis of CT26 cells treated with
PBS, DX alone (DX), or DX and z.VAD-fmk (DZ) for 24 h. Fig. S3 shows
the absence of NKT cells in HHD2 transgenic mice. Splenic cells were ob-
tained from both 6-wk-old female C57BL/6 and HHD2 transgenic mice
and then analyzed by cytofluorometry with antibodies against CD4, NK1.1,
and TCR   . Figs. S1–S3 are available at http://www.jem.org/cgi/content/
full/jem.20050915/DC1.
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